WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1996008239) USE OF 5-ALPHA-REDUCTASE INHIBITORS TO INCREASE HDL CHOLESTEROL LEVELS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1996/008239    International Application No.:    PCT/US1995/007215
Publication Date: 21.03.1996 International Filing Date: 06.06.1995
Chapter 2 Demand Filed:    21.02.1996    
IPC:
A61K 31/00 (2006.01), A61K 31/56 (2006.01), A61K 31/58 (2006.01)
Applicants: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US) (For All Designated States Except US).
TOBERT, Jonathan, A. [GB/US]; (US) (For US Only).
KAUFMAN, Keith, D. [US/US]; (US) (For US Only)
Inventors: TOBERT, Jonathan, A.; (US).
KAUFMAN, Keith, D.; (US)
Common
Representative:
MERCK & CO., INC.; Patent Dept., 126 East Lincoln Avenue, Rahway, NJ 07065 (US)
Priority Data:
304,905 13.09.1994 US
Title (EN) USE OF 5-ALPHA-REDUCTASE INHIBITORS TO INCREASE HDL CHOLESTEROL LEVELS
(FR) UTILISATION D'INHIBITEURS DE 5-ALPHA-REDUCASE POUR AUGMENTER LE TAUX DE CHOLESTEROL A LIPOPROTEINES DE HAUTE DENSITE
Abstract: front page image
(EN)The present invention relates to the use of 5$g(a)-reductase inhibitors to increase serum HDL cholesterol levels. These compounds may be used together with other lipid lowering agents, such as HMG-CoA reductase inhibitors, squalene synthase inhibitors, HMG-CoA synthase inhibitors, bile acid sequestrants, niacin, probucol, and the fibric acids to reduce the risk of coronary artery disease mortality. Further, two or more 5$g(a)-reductase inhibitors may be used in combination to increase serum HDL cholesterol levels.
(FR)Utilisation d'inhibiteurs de 5$g(a)-réductase pour augmenter le taux sérique de cholestérol à lipoprotéines de haute densité. Lesdits composés peuvent être utilisés avec d'autres hypolipémiants, tels que les inhibiteurs de HMG-CoA réductase, les inhibiteurs de squalène synthase, les inhibiteurs de HMG-CoA synthase, les séquestrants d'acide biliaire, la niacine, le probucol et les acides fibriques, pour réduire le risque de mortalité due aux coronaropathies. En outre, deux ou plusieurs inhibiteurs de 5$g(a)-réductase peuvent être utilisés en combinaison pour augmenter le taux sérique de cholestérol à lipoprotéines de haute densité.
Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ.
African Regional Intellectual Property Organization (KE, MW, SD, SZ, UG)
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)